Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib + Temozolomide in Advanced Acral Melanoma
NCT05789043Phase 3Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, Rivoceranib, temozolomide in acral lentiginous melanoma (ALM), sponsored by Peking University Cancer Hospital & Institute. Started Mar 2023; status: recruiting.
02
Drugs
camrelizumabRivoceranibtemozolomide
03
Conditions
acral lentiginous melanoma (ALM)
Beyond the preview
Go deeper on NCT05789043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05789043.